Partnership
InterMed Discovery (IMD), a natural product lead discovery company, has announced the start of a screening project for the Lead Discovery Center GmbH (LDC), a Max-Planck-Innovation company.
The objective is to identify drug leads by screening IMD’s natural product libraries against targets provided by LDC. IMD will generate assays, and carry out screening, hit identification and hit validation.
The LDC, founded in 2008 at the University Campus at Dortmund, is part of Max-Planck-Innovation’s Drug Discovery & Development Centre. It was set up to advance basic research, provide a full range of drug discovery services, and transform promising and early-stage projects into licensing or co-development opportunities.
Bert Klebl, Managing Director and chief scientific officer of LDC, said, “[We] aim to achieve the very highest levels of quality in early drug discovery and this objective is greatly enhanced by the collaboration with InterMed Discovery.”
InterMed Discovery was founded in 2006 as a management buyout of the Natural Products Research Unit of Bayer Healthcare.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
